Boardroom Alpha
Meeting calendar
MVIS · Annual meeting · Friday, July 10, 2026

Microvision Inc

7 nominees · 6 ballot items.

Elect seven directors; approve issuance of shares under the 2026 Convertible Notes; approve amendments to authorize a reverse stock split (1-for-5 to 1-for-15) and simultaneously reduce authorized shares to 150,000,000; approve, on a non-binding advisory basis, executive compensation (say-on-pay); ratify Baker Tilly US, LLP as independent auditors; and transact any other properly presented business.

Market cap
$28M
1Y TSR
-92.6%
Board grade
D
Record date
May 28, 2026
Filing
DEF 14A
Meeting concluded · Jul 10, 2026

Follow how the vote landed and what changed on Microvision Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot6

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect seven director nominees named in the proxy statement to serve until the next annual meeting.

  2. 2

    Approval of Issuance of Shares Pursuant to the 2026 Convertible Notes

    ManagementBoard: FOR

    Approve issuance of shares of the company’s common stock pursuant to senior secured convertible notes issued on February 23, 2026 to an institutional investor (the 2026 Convertible Notes) in accordance with Nasdaq rules.

    More detail

    This proposal requests shareholder approval to permit the issuance of common stock that could result from conversions or issuances under the company’s 2026 Convertible Notes, which were issued on February 23, 2026 in an aggregate principal amount of $43 million. Under Nasdaq Listing Rule 5635(d), shareholder approval is required for an issuance that could equal or exceed 20% of outstanding shares when issued at a price below the Minimum Price; obtaining this approval would remove the conversion cap (61,315,971 shares) that otherwise limits share issuance under the notes. Management and the Board argue that approval preserves the company’s ability to settle conversion or redemption obligations in shares rather than cash, conserving cash resources and mitigating liquidity strain; without approval the company may be forced to make substantial cash payments, increasing cash burn and potentially jeopardizing financing prospects. The Purchase Agreement with the Holder requires the company to use best efforts to obtain approval and contemplates repeated special meetings until approval is obtained if the Annual Meeting vote fails, indicating material commercial consequences of rejection. The Board recommends FOR approval on the basis that the Convertible Notes are senior secured debt that support near-term liquidity and strategic execution, while also noting customary anti-dilution protections and conversion price mechanics. Risks include potential dilution to existing shareholders if conversions occur and the fact that the conversion price may be below current market prices, depending on stock performance; the proposal balances immediate cash preservation against potential dilution. From a governance perspective, the transaction was negotiated with an institutional investor and the Board asserts no substantial direct interests by officers or directors, though conversion outcomes will affect ownership percentages. Approval would align the company’s capital structure with its financing plan to support commercialization and operations while providing flexibility for future capital needs.

  3. 3

    Approval of Amendments to the Company’s Certificate of Incorporation to Provide the Board the Right to Effect a Reverse Stock Split and Simultaneously Reduce Authorized Shares

    ManagementBoard: FOR

    Approve amendments permitting the Board to effect a reverse stock split at a whole-number ratio between 1-for-5 and 1-for-15 and simultaneously reduce authorized common shares to 150,000,000, with the Board to determine exact ratio and timing within one year.

    More detail

    The proposal asks shareholders to empower the Board to implement a reverse stock split at any whole-number ratio between 1-for-5 and 1-for-15 and to concurrently reduce authorized common shares from 510 million to 150 million, with the Board deciding the ratio and timing within one year. Management frames the split as a tool to regain compliance with Nasdaq’s $1.00 minimum bid-price requirement (or to facilitate a transfer to the Nasdaq Capital Market), improve the stock’s appeal to institutional investors, and preserve capital-raising flexibility; the definitive proxy explicitly states the Board modified the proposal after retail shareholder feedback to reduce authorized shares to 150 million to dispel concerns the split would facilitate future excessive dilution. The amendment, if effected, would reduce outstanding share counts and likely increase per-share market price, but the company cautions that market reaction may not be proportional and liquidity could be adversely affected; the proposal also warns of anti-takeover effects because the post-split increase in authorized but unissued shares could be used to dilute hostile bidders. The Board’s recommendation cites immediate listing risk and the strategic importance of maintaining Nasdaq listing and capital access; it also reserves the right to abandon the split even if authorized, and to determine not to proceed if conditions are unfavorable. The proxy provides concrete examples of post-split outstanding and authorized-available shares at illustrative ratios, and describes procedural, accounting, and fractional-share handling mechanics. Analysts should weigh the likelihood that the split will restore compliance and attract different investor classes against dilution concerns, potential reduced liquidity, and the asymmetry that authorized shares will not be reduced proportionally to outstanding shares, which increases the pool of authorized-for-issuance shares available post-split.

  4. 4

    Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers (Say-on-Pay

    ManagementBoard: FOR

    Approve, on a non-binding advisory basis, the compensation of the company’s named executive officers as disclosed in the proxy statement.

    More detail

    This non-binding advisory proposal asks shareholders to endorse the disclosed 2025 compensation paid to the company’s named executive officers. Management emphasizes a pay-for-performance philosophy, using at-risk compensation (including RSUs tied to performance and service conditions) to align executives with long-term shareholder value, and notes use of an independent compensation consultant in designing pay programs. A vote FOR signals shareholder acceptance of pay structure, allowing the Compensation Committee to consider the outcome when setting future compensation; a vote AGAINST would be advisory but could trigger engagement and potential changes to compensation practices. The proxy details significant elements such as performance-based RSUs, bonus targets tied to revenue and cash-operating-expense metrics, severance arrangements, and inducement awards for certain executives, which together shape both incentive alignment and potential dilution. Key considerations for assessment include the degree to which pay outcomes are tied to measurable performance (revenue, cash discipline, stock-price-based PRSUs), the balance of cash versus equity compensation given the company’s cash constraints, and recent leadership changes that affected compensation outcomes. The Board recommends FOR, citing recruitment and retention needs during commercialization and the desire to link pay to execution of strategic goals; dissenting shareholders often weigh dilution, one-time inducements, and realized pay versus performance when evaluating say-on-pay proposals. As an advisory vote, it carries no binding effect but remains an important governance signal influencing future pay decisions.

  5. 5

    Ratification of Selection of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify the appointment of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the current fiscal year.

  6. 6

    Other Business

    Management

    Transact any other business properly presented at the meeting.

Director elections

Nominees on the ballot7

Independent
Tenure on this board
9.7 yrs
Also a director at
Expeditors International Of Washington Inc (EXPD)
Ownership

Top institutional holders10

Latest 13F quarter
1VANGUARD CAPITAL MANAGEMENT LLC61.9%14,716,813$5M
2VANGUARD PORTFOLIO MANAGEMENT LLC26.2%6,230,084$2M
3BlackRock, Inc.15.0%3,564,466$1M
4GEODE CAPITAL MANAGEMENT, LLC13.5%3,218,072$1M
5MILLENNIUM MANAGEMENT LLC11.0%2,613,880$855K
6VANGUARD FIDUCIARY TRUST CO8.6%2,044,249$668K
7Sixth Street Partners Management Company, L.P.7.1%1,677,946$549K
8CHARLES SCHWAB INVESTMENT MANAGEMENT INC7.1%1,677,946$549K
9STATE STREET CORP6.5%1,550,777$507K
10UBS Group AG6.2%1,477,012$483K
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Microvision Inc 2026 annual meeting?
Microvision Inc (MVIS) holds its 2026 annual shareholder meeting on Friday, July 10, 2026.
What is the record date for the Microvision Inc 2026 meeting?
The record date for the Microvision Inc 2026 meeting is Thursday, May 28, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Microvision Inc's 2026 meeting?
The board is presenting 7 director nominees at the Microvision Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Microvision Inc 2026 meeting?
Shareholders will vote on 6 proposals at the Microvision Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer